ZEALAND PHARMA/S (NASDAQ:ZEAL) has been given a $26.00 price target by equities research analysts at Needham & Company LLC in a report released on Friday. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 84.14% from the stock’s previous close.

Separately, ValuEngine upgraded ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. ZEALAND PHARMA/S currently has an average rating of “Buy” and a consensus price target of $24.75.

Shares of ZEAL opened at $14.12 on Friday. ZEALAND PHARMA/S has a one year low of $12.01 and a one year high of $20.37.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last issued its quarterly earnings results on Wednesday, May 16th. The company reported ($0.49) EPS for the quarter. ZEALAND PHARMA/S had a negative return on equity of 75.66% and a negative net margin of 460.98%. The firm had revenue of $1.79 million for the quarter.

A hedge fund recently raised its stake in ZEALAND PHARMA/S stock. Millennium Management LLC raised its stake in ZEALAND PHARMA/S (NASDAQ:ZEAL) by 438.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 170,844 shares of the company’s stock after buying an additional 139,092 shares during the quarter. Millennium Management LLC owned approximately 0.56% of ZEALAND PHARMA/S worth $2,566,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.93% of the company’s stock.

About ZEALAND PHARMA/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Read More: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.